Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of KRT-232 in Relapsed or Refractory Small Cell Lung Cancer
2021-001530-19Phase 2Active
- Sponsor
- Kartos Therapeutics
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of navtemadlin in small cell lung cancer (SCLC), sponsored by Kartos Therapeutics. Primary endpoint: Objective response rate (ORR). Started Sep 2021; status: active.
02
Drugs
navtemadlin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2021-001530-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001530-19.